BHCM
IOVA icon

Brevan Howard Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Brevan Howard Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Buy
+81,981
New +$311K ﹤0.01% 1632
2026
Q1 		– Sell
-525,519
Closed -$1.68M – 2293
2025
Q4 		$1.43M Buy
525,519
+253,552
+93% +$587K 0.02% 608
2025
Q3 		$590K Sell
271,967
-89,836
-25% -$212K ﹤0.01% 1193
2025
Q2 		$622K Buy
361,803
+254,188
+236% +$632K ﹤0.01% 1259
2025
Q1 		$358K Buy
107,615
+95,653
+800% +$493K ﹤0.01% 811
2024
Q4 		$88.5K Sell
11,962
-22,159
-65% -$205K ﹤0.01% 975
2024
Q3 		$320K Buy
34,121
+10,350
+44% +$98.1K ﹤0.01% 826
2024
Q2 		$191K Sell
23,771
-209,559
-90% -$2.25M ﹤0.01% 902
2024
Q1 		$3.46M Sell
233,330
-459,445
-66% -$5.35M 0.03% 99
2023
Q4 		$5.63M Sell
692,775
-869,911
-56% -$4.55M 0.07% 40
2023
Q3 		$7.11M Buy
1,562,686
+81,251
+5% +$530K 0.09% 32
2023
Q2 		$10.4M Buy
1,481,435
+947,265
+177% +$6.78M 0.22% 24
2023
Q1 		$3.26M Buy
534,170
+254,338
+91% +$1.75M 0.09% 61
2022
Q4 		$1.79M Hold
279,832
– – 0.06% 48
2022
Q3 		$2.68M Buy
279,832
+75,774
+37% +$874K 0.1% 34
2022
Q2 		$2.25M Buy
+204,058
New +$2.67M 0.09% 22

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Brevan Howard Capital Management's IOVA Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 81,981 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #1632 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in IOVA as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in IOVA in Q2 2022 and has held it in 16 quarters since. The position peaked at $10.4M in Q2 2023. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Brevan Howard Capital Management held 81,981 shares of Iovance Biotherapeutics worth $341K as of Q2 2026.
  • Iovance Biotherapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1632 holding.
  • Brevan Howard Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • Brevan Howard Capital Management's Iovance Biotherapeutics position peaked at $10.4M in Q2 2023.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.